Collectively, current evidence suggests that an activated IL-33/ST2 axis might have a potential effect on the development of esophageal inflammation in EoE, GERD, and esophageal cancer by multiple mechanisms. This evidence concerns the gene IL33 and gastroesophageal reflux disease.